Verification and safety standard
Our five-gate framework separates public claims from current clinical access, medical eligibility and a formal hospital plan.
Two checks that must remain separate
Check regulatory status (a specific approved use, research protocol or unverified offer) separately from international access (current intake and individual eligibility). “Access pending” does not establish that the underlying treatment is authorised.
- China: biomedical new-technology regulation (Articles 20, 29–34 and 58)
- NMPA announcement reproduced by CCFDIE: conditional approval of 艾米迈托赛注射液 (2 January 2025)
Status and source check: · RMC editorial review of the linked sources. No clinician review or individual eligibility decision is claimed.
A pathway is not promoted as accessible until each layer is checked.
The standard is designed for international patients, who face different practical barriers from domestic patients.
Regulatory pathway
Clinical application, drug or device trial, registered research or research only.
Treating institution
Hospital, department, responsible medical team and active programme status.
International access
Passport eligibility, remote review, language support, payment and follow-up.
Eligibility pathway
Required records, inclusion factors, exclusions, tests and realistic goals.
Formal plan and price
Written institutional instructions, consent, schedule, medical quotation and support fees.
What the labels on this website mean
We use language that reflects what has actually been checked, not what a patient may hope to hear.
Foreign patients can request review
The institution has confirmed a current route for international cases. Eligibility is still decided individually.
Domestic pathway identified
A credible clinical pathway exists publicly, but foreign-patient intake, criteria or pricing still need direct confirmation.
Research protocol and recruitment
Access depends on the protocol and study team. Participation is not sold as a routine treatment package.
Evidence or early clinical work
The topic may be scientifically relevant, but no verified clinical access route is presented.
How we weigh information
A commercial website can help identify a lead, but it should not be the final source for approval, access or clinical evidence.
Government and regulator
Official laws, decisions, policy and recognised registries.
Treating institution
Hospital, department, medical team and written patient instructions.
Peer-reviewed evidence
Product- and indication-specific studies, methods and limitations.
Commercial information
Useful as a lead, but independently verified before being treated as fact.
Questions we expect a credible pathway to answer
- What exactly is being administered or performed?
- What condition and disease stage is being targeted?
- What evidence supports the proposed outcome?
- What risks, uncertainties and alternatives are disclosed?
- Who manages complications and long-term follow-up?
- Can the patient obtain written consent documents and an itemised quotation?
Frequently asked questions
It means the institution has confirmed that foreign patients can currently request review through a defined process. It does not mean every patient qualifies.
Foreign-patient intake may require separate documents, language support, follow-up and institutional approval.
High-interest pathways should be rechecked regularly and whenever the institution changes its policy, price or recruitment status.
Yes. Status and evidence are separate: a lawful pathway can still have limited evidence, and a promising study may not be clinically accessible.
It can be a research lead, but it should be checked against official, hospital, registry and peer-reviewed sources where possible.
We present the uncertainty, prioritise authoritative sources and seek direct confirmation from the responsible institution.
Verify before you commit.
Submit a case or an existing treatment offer. We will identify the claims that need official, institutional or clinical confirmation.